fr

CARMAT provides update on the renegotiation of the repayment terms of its loans with its financial creditors

 

  • Agreement in principle on the rescheduling of State-Guaranteed Loans (“PGE”) obtained from BNP Paribas and Bpifrance
  • Extension of the standstill granted by the EIB, BNP Paribas and Bpifrance until March 22, 2024, to facilitate the conclusion of a final agreement covering all financial debts by that date

 

Paris, February 22, 2024 – 7 am (CET)

 

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the renegotiation of the repayment terms of its loans with its financial creditors.

 

Conditional agreement in principle with the European Investment Bank (“EIB”)

As a reminder, CARMAT reached a conditional agreement in principle with the EIB[1] in January 2024 regarding all three tranches of its loan[2]. This agreement notably provides for the postponement of the due date for the first tranche of the loan (total amount of approximately €15 million[3] in principal and interest) to July 31, 2026, as well as the postponement of the due dates for the other two tranches, respectively to August 2027 and October 2028.

If implemented, this agreement would allow CARMAT to avoid having to repay this loan before July 31, 2026[4]. As a reminder, the first tranche of the loan was initially due on January 31, 2024, and the second and third tranches in 2025 and 2026, respectively.

This agreement in principle is not binding at this stage, as it is in particular subject to the conclusion of a rescheduling agreement for the State-Guaranteed Loans (PGE) contracted by the Company with BNP Paribas (BNPP) and Bpifrance (BPI), for a total principal amount of €10 million[5].

 

Agreement in principle on the rescheduling of State-Guaranteed Loans

During February 2024, CARMAT obtained an agreement in principle from both BNP Paribas and Bpifrance on the rescheduling of the two PGEs contracted with these banks, the initial maturity of which was set for the fourth quarter of 2026. This agreement is itself conditional, notably on the implementation of the agreement reached with the EIB.

 

Extension of the standstill to allow the finalization of a final agreement with all financial creditors by March 22, 2024

To facilitate the finalization of the discussions with the banks, the standstill applicable to the principal of the various loans, which had previously been granted by the EIB, BNPP, and BPI until February 22, 2024, has been extended until March 22, 2024.

By that date, the Company anticipates reaching a final agreement on the rescheduling of all its financial debts contracted with the EIB, BNP Paribas, and Bpifrance.

In such a case, given this agreement and its cash position, the Company could, based on to its current business plan, fund its activities until mid-May 2024, and estimates its financing needs over the next 12 months at approximately €35 million.

However, it is not guaranteed that such an agreement will be reached by March 22, 2024. In this scenario, which the Company does not consider the most likely, CARMAT could have its cash runway reduced to March 22, 2024, and its financing needs over the next 12 months increased to approximately €50 million.

The Company carries on working very actively on other initiatives to strengthen its equity and alleviate its cash constraints in the short term.

 

Stéphane Piat, CEO of CARMAT, comments: “The agreements in principle reached with the EIB on one hand, and BNP Paribas and Bpifrance on the other hand, regarding new repayment terms for their respective loans, represent a very positive development.

I am confident that by March 22, the discussions with these three banks will get finalised and a final agreement on the rescheduling of all our financial debts will be reached.

I would like to thank again our three banking partners for their commitment by our side.”

 

[1] Press Release from January 12, 2024, regarding the conditional agreement in principle with the EIB

[2] Under a contract concluded on December 17, 2018, the Company secured a loan from the EIB amounting to €30m disbursed in 3 tranches of €10m each, on January 31, 2019 (the “first tranche”), May 4, 2020 (the “second tranche”), and October 29, 2021 (the “third tranche” and, together with the other tranches, the “tranches”), each tranche to be repaid, in principal and interest, 5 years after its disbursement to the Company.

[3] Principal of €10m and interest of approximately €5m

[4] Except in cases of default or early repayment, which would remain unchanged.

[5] Two State-Guaranteed Loans (PGE) contracted in the fourth quarter of 2020, respectively from BNP Paribas and Bpifrance, with a principal amount of €5m each, amortizable from the fourth quarter of 2022 to the fourth quarter of 2026.

Download

Paris, February 5, 2024 – 5:45 pm CET

 

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announces its indicative financial calendar for 2024.

 

This preliminary agenda may be modified. Each publication will be released before market opening.

 

Event

Date

2023 Full-Year Results

Wednesday, April 24, 2024

Shareholders’ Meeting

Thursday, May 30, 2024

2024 Half-Year Results

Wednesday, September 11, 2024

Download

  • 50 patients have benefited from CARMAT’s Aeson® artificial heart since the first implant in 2013
  • Aeson® becomes an essential breakthrough innovation in the treatment of advanced biventricular heart failure
  • 41 hospitals in 12 countries are trained for implants[1], including 33 for commercial activity
  • Turnover of €2.8m in 2023, marked by a substantial acceleration in sales in the fourth quarter, with 11 implants out of the 17 carried out during the year
  • Sales of €14-20m anticipated in 2024
  • Launch in the very short term of a capital increase to extend the cash runway beyond the end of January 2024 and partially finance the Company’s needs for the forthcoming 12-month period, estimated to a minimum of €50m

 

 

Videoconference on January 17 at 20:00 CET.

To participate, please register by clicking on this link

 

Paris, January 15, 2024 – 7:00 am (CET)

 

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announced that it has reached the milestone of 50 implants of its total artificial heart, and provides an update on its achievements and outlook.

 

Stéphane Piat, Chief Executive Officer of CARMAT, declares: « CARMAT celebrated its 15th anniversary in 2023. The Company and its teams are extremely proud to have reached the milestone of 50 Aeson® implants since the first in December 2013. This milestone is a major success and is a testimony of the recognition of our therapy by leading names in cardiology.

Founded on the work of the icon of cardiac surgery, Professor Alain Carpentier, CARMAT aims to treat heart failure, a major health issue and the world’s leading cause of death, by replacing the diseased heart with a bioprosthetic artificial heart. The last 15 years have been a period of intense research and development, resulting in a breakthrough innovation that is unique in the field of cardiology. 2023 has been particularly structuring year for the Company, with a substantial acceleration in sales in the last quarter, a significant number of hospitals trained for implants, increased manufacturing capacity to meet demand, and a reinforcement of the Aeson® heart’s safety profile thanks, in particular, to software improvements, which represents a significant catalyst for our long-term ambition to make Aeson® a “destination therapy” device, i.e. enabling long-term patient support without subsequent heart transplantation.

Taken together, these advances provide a solid foundation for a sizable commercial roll-out, enabling CARMAT to achieve its ultimate goal of providing patients waiting for a human heart with a therapeutic solution and a good quality of life. We look forward to 2024 with confidence and are very determined to achieve our goals. »

[1] Excluding the United States, where 9 hospitals are trained as part of the EFS (early feasibility study) clinical trial.

Download

  • In compliance with regulations, the implementation of this modification gives rise to the publication of a “field safety notice”.
  • Its roll-out will begin over the next few days.

 

Paris, December 28, 2023 – 5:45 pm (CET)

 

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announced a software enhancement which significantly improves the safety profile of its Aeson® artificial heart.

 

The prosthesis software will now be able to detect on a real time basis, signals of possible Aeson® malfunctions. The software will then immediately adapt the control of the prosthesis so that its performance is not affected, and the patient’s support is not impacted.

 

These changes, developed and tested by CARMAT’s research teams, will first be deployed on all hearts currently implanted in patients, as part of a software update for which a field safety notice is published[1]. It will then be embedded into the Aeson® production process, after getting the appropriate regulatory approvals.

 

Stéphane Piat, Chief Executive Officer of CARMAT, declares: “In all industries, electronic components are potentially subject to failure, because perfection of their manufacturing is almost impossible to achieve. It was important to be able to manage such risks in the case of our device, and I’m therefore very proud of the feat achieved by our software engineers: from now on, for many of the potential malfunctions linked to the prosthesis’s electronic components, Aeson® software will automatically “correct” these faults by adapting the prosthesis’s performance in an appropriate manner, so that the patient’s support remains unaffected. For me, this is a major and immediate step forward for all the patients who benefit and will benefit from our therapy; but also in the long term, when it comes to obtaining the destination therapy indication for Aeson®, as this improvement significantly strengthens the safety profile and therefore the potential durability of the prosthesis.”

[1] In France, publication is made on the ANSM health authority website.

Download

  • This world first for Aeson® was achieved by teams at the Marie-Lannelongue Hospital in France as part of the EFICAS® study
  • The Marie-Lannelongue Hospital is one of the 8 French centers approved to carry out implants as part of this study
  • Enrolment of the first 10-patient cohort of the study has been completed

Paris, December 11, 2023 – 5:45 pm (CET)

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announced the first implantation of the Aeson® heart in a patient suffering from a cardiac tumor.

The patient implanted was suffering from a tumor invading the heart mass, responsible for rhythmic and restrictive cardiopathy, which eluded standard medical treatment. Only complete surgical removal of the heart could be considered as a hope of treatment. It is in this context that the Aeson® total artificial heart was implanted for the first time in the world in this type of indication.

The implant was carried out at the Marie-Lannelongue Hospital in Plessis-Robinson (in the western suburbs of Paris) by the teams of Professor Julien Guihaire, cardiac surgeon, and Professor Elie Fadel, thoracic surgeon.

Prof. Julien Guihaire and Prof. Elie Fadel said: “We are delighted to have been able to provide a solution to this patient in a very difficult situation, for whom there was no other alternative than a total heart replacement with Aeson®. This first-in-man implant performed in our hospital is a continuation of the commitment to the CARMAT project by our teams since the beginning of 2010, including in particular the performance of numerous implant simulations in the Marie-Lannelongue Hospital research laboratory. Aeson® offers real hope for patients with invasive cardiac tumors whose treatment options and survival are currently extremely limited.”

The implant was performed as part of the CARMAT’s EFICAS study, which aims to gather additional data on the efficacy and safety of its Aeson® artificial heart, as well as medico-economic data to support the value proposition of the prosthesis, and in particular the reimbursement of the device in France.

Eight French cardiology centers[1] are now involved in the EFICAS study, which will include a total of 52 patients. To date, enrolment of the first cohort of 10 patients has been finalized, and the study is on track for completion in 2025.

 

Stéphane Piat, Chief Executive Officer of CARMAT, concludes: “I would like to thank the teams at the Marie-Lannelongue Hospital, a long-standing partner, for giving new hope to a patient suffering from major comorbidities. We are delighted with this world first for CARMAT, which demonstrates the ability of Aeson® to address increasingly complex clinical cases.”

 

●●

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).

For more information, please go to www.carmatsa.com and follow us on LinkedIn.

 

 

 

CARMAT

Stéphane Piat

Chief Executive Officer

 

Pascale d’Arbonneau

Chief Financial Officer

Tel.: +33 1 39 45 64 50

contact@carmatsas.com

 

 

 

Alize RP

Press Relations

 

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

carmat@alizerp.com

NewCap

Financial Communication
& Investor Relations

 

Dusan Oresansky

Quentin Massé

Tel.: +33 1 44 71 94 92

carmat@newcap.eu

 

 

 

 

 

Name: CARMAT

ISIN code: FR0010907956

Ticker: ALCAR

 

 

●●

About the Marie-Lannelongue Hospital

The Marie-Lannelongue Hospital is a private health establishment of collective interest (ESPIC) in sector 1 (with no out-of-pocket expenses) specializing in the medical, surgical and minimally invasive treatment of cardiac, pulmonary and vascular pathologies. Recognized as a center of excellence in France and internationally, it treats congenital heart malformations, diseases and tumors of the thoracic cavity, pulmonary arterial hypertension and valvular heart disease or coronary artery disease from newborns to adults. The technical expertise of its teams, combined with cutting-edge technology, make it one of the world’s leading hospitals in pediatric and adult cardiology and thoracic oncology.

The Marie-Lannelongue Hospital is currently being rebuilt in Plessis-Robinson (in the western suburbs of Paris). The new hospital is due to open in 2025.

 

Contacts Media Relations– Hôpitaux Saint-Joseph & Marie-Lannelongue
Fabienne Rouhier – presse@ghpsj.fr
Alix Fournier – presse@ghpsj.fr 
Tel.: +33 1 44 12 80 95

For more information: www.hopitalmarielannelongue.fr

 

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT (the “Company”) in any country. This press release may contain forwardlooking statements that relate to the Company’s objectives and prospects. Such forwardlooking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties including, without limitation, the Company’s ability to successfully implement its strategy, the rate of development of CARMAT’s production and sales, the pace and results of ongoing and future clinical trials, new products or technological developments introduced by competitors, changes in regulations and risks associated with growth management. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

The significant and specific risks pertaining to the Company are those described in the Universal Registration Document (“Document d’Enregistrement Universel”) filed with the Autorité des Marchés Financiers (AMF, the French stock market authorities) under number D. 23-0323. Readers’ attention is drawn in particular to the financing risk of the Company, whose cash runway currently extends until early 2024. Readers and investors’ attention is also drawn to the fact that other risks, unknown or not deemed to be significant or specific, may or could exist.

Aeson® is an active implantable medical device commercially available in the European Union and other countries that recognize CE marking. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who are not amenable to maximal medical therapy or a left ventricular assist device (LVAD) and are likely to undergo a heart transplant within 180 days of the device being implanted. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual and alarm booklet) should be read carefully to understand the characteristics of Aeson® and information necessary for patient selection and the proper use of Aeson® (contraindications, precautions, side effects). In the United States, Aeson® is currently exclusively available within the framework of an Early Feasibility Study authorized by the Food & Drug Administration (FDA)

[1] AP-HP GHU Pitié Salpêtrière, Hôpital Européen Georges Pompidou, Rennes University Hospital, Strasbourg University Hospital, Lyon University Hospital, Lille University Hospital, Marie-Lannelongue Hospital and Montpellier University Hospital

Download

  • The facility and its equipment meet the highest standards for the production of medical devices
  • Its opening will enable the Company to reach a production capacity of 500 hearts per year as early as 2024, in line with its objectives

Paris, December 4, 2023 – 5:45 pm (CET)

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today announced the opening of its second production facility (“BDA2”) in Bois-d’Arcy, in the immediate vicinity of the Company’s first production facility (“BDA1”).

The works have now been completed, and the entire facility has been reviewed by the notified body DEKRA, which in mid-November 2023 approved it for the production of the Aeson® total artificial heart.

This 1,500 m2 building, which meets the highest medical device production standards, will enable CARMAT to significantly increase its capacity in terms of:

  • assembly of the electronic parts of the Aeson® heart,
  • microbiological testing of the product and the manufacturing process,
  • receiving and checking incoming components,
  • storage and shipping.

Combined with the extension of the clean room which is currently being completed in the “BDA1” facility, the opening of the “BDA2” facility will enable the Company to reach an annual production capacity of 500 hearts by early 2024, as planned.

Stéphane Piat, Chief Executive Officer of CARMAT, comments: “The opening of our new production facility is a major achievement, and I would like to thank all the teams who have worked relentlessly to ensure that it is delivered on schedule before the end of 2023. Today, with the historical “BDA1” facility and this new “BDA2″ facility, we have a high-performance manufacturing tool that is certified to produce up to 500 hearts per year from 2024. In line with our strategic plan, we will further develop our industrial set-up over the next few years, to reach an annual production capacity of 1,000 Aeson® hearts by 2027.”

 

***

 

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).

For more information, please go to www.carmatsa.com and follow us on LinkedIn.

  • ●●

 

 

CARMAT

Stéphane Piat

Chief Executive Officer

 

Pascale d’Arbonneau

Chief Financial Officer

Tel.: +33 1 39 45 64 50

contact@carmatsas.com

 

 

 

Alize RP

Press Relations

 

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

carmat@alizerp.com

NewCap

Financial Communication
& Investor Relations

 

Dusan Oresansky

Quentin Massé

Tel.: +33 1 44 71 94 92

carmat@newcap.eu

 

 

 

 

 

Name: CARMAT

ISIN code: FR0010907956

Ticker: ALCAR

 

 

  • ●●

 

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT (the “Company”) in any country. This press release may contain forwardlooking statements that relate to the Company’s objectives and prospects. Such forwardlooking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties including, without limitation, the Company’s ability to successfully implement its strategy, the rate of development of CARMAT’s production and sales, the pace and results of ongoing and future clinical trials, new products or technological developments introduced by competitors, changes in regulations and risks associated with growth management. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

The significant and specific risks pertaining to the Company are those described in the Universal Registration Document (“Document d’Enregistrement Universel”) filed with the Autorité des Marchés Financiers (AMF, the French stock market authorities) under number D. 23-0323. Readers and investors’ attention is, however, drawn to the fact that other risks, unknown or not deemed to be significant or specific, may or could exist.

Aeson® is an active implantable medical device commercially available in the European Union and other countries that recognize CE marking. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who are not amenable to maximal medical therapy or a left ventricular assist device (LVAD) and are likely to undergo a heart transplant within 180 days of the device being implanted. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual and alarm booklet) should be read carefully to understand the characteristics of Aeson® and information necessary for patient selection and the proper use of Aeson® (contraindications, precautions, side effects). In the United States, Aeson® is currently exclusively available within the framework of an Early Feasibility Study authorized by the Food & Drug Administration (FDA).

 

 

 

Download
Top of page